NASDAQ:TNDM - Tandem Diabetes Care Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $123.11
Forecasted Upside: 20.64 %
Number of Analysts: 9
Breakdown:
1 Sell Ratings
2 Hold Ratings
6 Buy Ratings
0 Strong Buy Ratings

^$102.05 As of 07/27/2021 01:00 AM ET

▼ -0.3 (-0.29%)

1 month | 3 months | 12 months

Get New Tandem Diabetes Care Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for TNDM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TNDM

^$123.11

▲ +20.64% Upside Potential

This price target is based on 9 analysts offering 12 month price targets for Tandem Diabetes Care in the last 3 months. The average price target is $123.11, with a high forecast of $150.00 and a low forecast of $90.00. The average price target represents a 20.64% upside from the last price of $102.05.

Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Tandem Diabetes Care. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

2/4/2020

0 strong buy ratings
9 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

5/4/2020

0 strong buy ratings
9 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

8/2/2020

0 strong buy ratings
9 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

10/31/2020

0 strong buy ratings
9 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

1/29/2021

0 strong buy ratings
9 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

4/29/2021

0 strong buy ratings
8 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

6/28/2021

0 strong buy ratings
6 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

7/28/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/24/2021	Barclays	Initiated Coverage	Underweight	$90.00	Low
5/6/2021	Oppenheimer	Boost Price Target		$130.00 ➝ $135.00	Low
5/6/2021	SVB Leerink	Boost Price Target	Market Perform	$95.00 ➝ $102.00	High
4/1/2021	SVB Leerink	Lower Price Target	Market Perform	$115.00 ➝ $95.00	Low
3/31/2021	Oppenheimer	Reiterated Rating	Buy		High
2/25/2021	Lake Street Capital	Boost Price Target	Buy	$137.00 ➝ $150.00	High
12/15/2020	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$105.00	High
11/6/2020	Raymond James	Boost Price Target	Outperform	$116.00 ➝ $124.00	High
11/6/2020	SVB Leerink	Boost Price Target	Market Perform	$120.00 ➝ $130.00	High
11/6/2020	Piper Sandler	Boost Price Target	Overweight	$125.00 ➝ $132.00	High
9/21/2020	Oppenheimer	Reiterated Rating	Buy	$120.00	High
8/28/2020	SVB Leerink	Boost Price Target	Market Perform	$115.00 ➝ $120.00	Low
8/20/2020	Wells Fargo & Company	Initiated Coverage	Overweight	$120.00	High
7/31/2020	Raymond James	Boost Price Target	Outperform	$95.00 ➝ $116.00	Low
7/31/2020	Craig Hallum	Boost Price Target	Buy	$102.00 ➝ $140.00	High
7/31/2020	Lake Street Capital	Boost Price Target	Positive ➝ Buy	$125.00 ➝ $137.00	High
7/31/2020	SVB Leerink	Boost Price Target	Market Perform	$105.00 ➝ $115.00	High
7/31/2020	Guggenheim	Upgrade	Neutral ➝ Buy	$130.00	High
7/31/2020	Piper Sandler	Boost Price Target	Overweight	$90.00 ➝ $125.00	High
7/7/2020	Cowen	Boost Price Target	Positive ➝ Outperform	$85.00 ➝ $110.00	Low
7/6/2020	Citigroup	Upgrade	Neutral ➝ Buy	$94.00 ➝ $120.00	Low
6/30/2020	Oppenheimer	Initiated Coverage	Buy	$102.00	Low
6/30/2020	Piper Sandler	Reiterated Rating	Buy	$90.00	Low
6/30/2020	Bank of America	Reiterated Rating	Hold	$100.00	Low
6/30/2020	Cowen	Reiterated Rating	Buy	$85.00	Low
6/22/2020	UBS Group	Boost Price Target	Buy	$98.00 ➝ $106.00	Low
6/22/2020	Oppenheimer	Boost Price Target	Reduce ➝ Outperform	$92.00 ➝ $102.00	Low
6/18/2020	Lake Street Capital	Boost Price Target		$100.00 ➝ $125.00	Low
6/18/2020	Raymond James	Boost Price Target	Outperform	$88.00 ➝ $95.00	Low
6/17/2020	Oppenheimer	Initiated Coverage	Buy	$92.00	Low
6/3/2020	Citigroup	Boost Price Target	Average ➝ Neutral	$81.00 ➝ $94.00	Low
5/22/2020	Bank of America	Boost Price Target	Neutral	$85.00 ➝ $95.00	Low
5/1/2020	UBS Group	Lower Price Target	Buy	$100.00 ➝ $98.00	High
5/1/2020	Citigroup	Boost Price Target	Neutral	$74.00 ➝ $81.00	High
5/1/2020	Stifel Nicolaus	Boost Price Target	Hold	$65.00 ➝ $75.00	Medium
5/1/2020	Oppenheimer	Reiterated Rating	Buy	$92.00	High
5/1/2020	SVB Leerink	Boost Price Target	Market Perform	$85.00 ➝ $88.00	High
4/27/2020	Raymond James	Lower Price Target	Outperform	$91.00 ➝ $81.00	Low
4/24/2020	SVB Leerink	Downgrade	Outperform ➝ Market Perform		Low
4/20/2020	Craig Hallum	Lower Price Target	Buy	$108.00 ➝ $102.00	Medium
3/27/2020	Citigroup	Lower Price Target	Neutral	$89.00 ➝ $74.00	High
3/23/2020	Guggenheim	Downgrade	Buy ➝ Neutral		High
3/4/2020	Citigroup	Initiated Coverage	Neutral	$89.00	Medium
2/25/2020	Oppenheimer	Boost Price Target		$84.00 ➝ $97.00	High
2/25/2020	Piper Sandler	Boost Price Target	Overweight	$70.00 ➝ $90.00	High
2/25/2020	Craig Hallum	Boost Price Target	Buy	$92.00 ➝ $108.00	High
2/25/2020	Stifel Nicolaus	Boost Price Target	Hold	$70.00 ➝ $77.00	High
2/25/2020	Raymond James	Boost Price Target	Outperform	$85.00 ➝ $91.00	High
2/25/2020	Cowen	Reiterated Rating	Outperform	$85.00 ➝ $90.00	High
2/13/2020	Cowen	Boost Price Target	Outperform	$70.00 ➝ $85.00	Medium
2/12/2020	Craig Hallum	Reiterated Rating	Buy	$92.00	High
2/5/2020	Raymond James	Initiated Coverage	Outperform	$85.00	Low
2/4/2020	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$71.00 ➝ $75.00	Low
12/13/2019	Craig Hallum	Reiterated Rating	Buy	$92.00	Low
10/17/2019	Guggenheim	Initiated Coverage	Buy	$76.00	Low
10/4/2019	UBS Group	Upgrade	Neutral ➝ Buy	$75.00	Low
8/2/2019	Oppenheimer	Boost Price Target		$80.00 ➝ $84.00	Medium
6/17/2019	Lake Street Capital	Reiterated Rating	Buy		Medium
5/17/2019	Bank of America	Reiterated Rating	Neutral	$65.00	Medium
5/13/2019	SVB Leerink	Initiated Coverage	Outperform ➝ Outperform	$83.00	Low
5/1/2019	Oppenheimer	Boost Price Target	Outperform	$68.00 ➝ $80.00	Medium
5/1/2019	Stifel Nicolaus	Boost Price Target	Hold ➝ Hold	$58.00 ➝ $70.00	Medium
5/1/2019	Craig Hallum	Reiterated Rating	Buy	$70.00 ➝ $84.00	High
4/30/2019	UBS Group	Boost Price Target	Neutral ➝ Neutral	$53.00 ➝ $66.00	High
3/8/2019	BMO Capital Markets	Initiated Coverage	Outperform ➝ Outperform	$77.00	High
3/5/2019	Bank of America	Boost Price Target	Neutral	$59.00 ➝ $65.00	Low
2/27/2019	Oppenheimer	Boost Price Target	Outperform	$57.00 ➝ $68.00	Medium
2/27/2019	Cowen	Boost Price Target	Outperform	$40.00 ➝ $60.00	Medium
2/27/2019	Craig Hallum	Boost Price Target	Buy	$59.00 ➝ $70.00	Medium
2/27/2019	Lake Street Capital	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $100.00	High
2/27/2019	Piper Jaffray Companies	Upgrade	Overweight	$67.00	High
2/15/2019	Robert W. Baird	Boost Price Target	Outperform	$46.00 ➝ $55.00	Medium
11/27/2018	UBS Group	Initiated Coverage	Neutral	$36.00	High
11/21/2018	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$46.00	High
11/9/2018	Oppenheimer	Set Price Target	Buy	$57.00	Medium
11/3/2018	Lake Street Capital	Set Price Target	Buy	$60.00	High
11/2/2018	Craig Hallum	Set Price Target	Buy	$59.00	High
11/2/2018	Oppenheimer	Set Price Target	Buy	$57.00	High
10/15/2018	Lake Street Capital	Set Price Target	Buy	$60.00	High
9/26/2018	Dougherty & Co	Boost Price Target	Buy	$45.00 ➝ $56.00	Low
9/26/2018	Piper Jaffray Companies	Reiterated Rating	Above Average ➝ Overweight	$32.00 ➝ $56.00	Medium
9/25/2018	Oppenheimer	Reiterated Rating	Buy	$57.00	Low
9/20/2018	Craig Hallum	Initiated Coverage	Buy	$52.00 ➝ $52.00	Low
9/14/2018	Robert W. Baird	Downgrade	Outperform ➝ Neutral		Medium
9/5/2018	Oppenheimer	Set Price Target	Buy	$54.00	High
8/30/2018	Berenberg Bank	Initiated Coverage	Buy ➝ Buy	$50.00	High
8/24/2018	Dougherty & Co	Initiated Coverage	Buy ➝ Buy	$45.00	High
8/24/2018	Bank of America	Upgrade	Underperform ➝ Neutral	$45.00	High
8/22/2018	Stifel Nicolaus	Initiated Coverage	Hold	$25.00 ➝ $34.00	High
8/20/2018	Lake Street Capital	Boost Price Target	Buy	$35.00 ➝ $65.00	Low
8/6/2018	Oppenheimer	Set Price Target	Buy	$31.00 ➝ $38.00	High
7/31/2018	Oppenheimer	Set Price Target	Buy	$31.00	High
7/31/2018	Lake Street Capital	Boost Price Target	Buy	$35.00	High
7/31/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$32.00	High
7/31/2018	Stifel Nicolaus	Reiterated Rating	Hold ➝ Hold	$7.50 ➝ $25.00	High
7/31/2018	Cowen	Reiterated Rating	Buy	$28.00	High
7/23/2018	Robert W. Baird	Reiterated Rating	Buy	$31.00	High
6/22/2018	Piper Jaffray Companies	Upgrade	Overweight	$25.00	High
6/18/2018	Lake Street Capital	Initiated Coverage	Buy	$30.00	High
5/27/2018	Oppenheimer	Set Price Target	Buy	$15.00	High
5/21/2018	Oppenheimer	Set Price Target	Buy	$10.00 ➝ $15.00	High
5/14/2018	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight		High
4/6/2018	Oppenheimer	Set Price Target	Buy	$8.00	High
3/28/2018	Cowen	Upgrade	Market Perform ➝ Outperform		Medium
3/23/2018	Robert W. Baird	Upgrade	Neutral ➝ Outperform		High
3/22/2018	Oppenheimer	Reiterated Rating	Buy		Medium
3/2/2018	Stifel Nicolaus	Reiterated Rating	Hold	$4.00	High
2/27/2018	Cowen	Reiterated Rating	Hold		Medium
2/27/2018	Citigroup	Initiated Coverage	Outperform	$5.50	Low
2/26/2018	Oppenheimer	Initiated Coverage	Buy	$5.50 ➝ $6.00	High
11/19/2017	Robert W. Baird	Reiterated Rating	Hold	$3.00	N/A
10/10/2017	Wedbush	Reiterated Rating	Outperform	$50.00 ➝ $17.00	N/A
10/6/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$15.00	N/A
5/3/2017	B. Riley	Reiterated Rating	Neutral	$15.00	Medium
4/28/2017	B. Riley	Reiterated Rating	Neutral	$15.00	Low
4/10/2017	Cowen	Downgrade	Outperform ➝ Market Perform	$15.00	Medium
3/30/2017	Wedbush	Reiterated Rating	Outperform	$110.00	Low
3/30/2017	Piper Jaffray Companies	Reiterated Rating	Neutral ➝ Neutral		Medium
3/29/2017	B. Riley	Downgrade	Neutral	$15.00	Medium
3/24/2017	B. Riley	Downgrade	Buy ➝ Neutral	$50.00 ➝ $15.00	Low
3/11/2017	B. Riley	Reiterated Rating	Buy	$50.00	N/A
3/9/2017	Northcoast Research	Reiterated Rating	Buy		N/A
1/24/2017	Wedbush	Reiterated Rating	Positive		N/A
11/7/2016	B. Riley	Reiterated Rating	Buy	$70.00	N/A
11/3/2016	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral		N/A
11/2/2016	B. Riley	Reiterated Rating	Buy	$70.00	N/A
11/2/2016	Deutsche Bank Aktiengesellschaft	Lower Price Target	Buy	$140.00 ➝ $90.00	N/A
11/2/2016	Feltl & Co.	Downgrade	Strong-Buy ➝ Buy		N/A
11/2/2016	Wedbush	Lower Price Target	Outperform	$200.00 ➝ $110.00	N/A
11/2/2016	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$110.00 ➝ $40.00	N/A
11/2/2016	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$150.00 ➝ $35.00	N/A
10/2/2016	B. Riley	Initiated Coverage	Buy	$100.00	N/A
9/26/2016	B. Riley	Initiated Coverage	Buy	$100.00	N/A
7/29/2016	Wedbush	Reiterated Rating	Outperform	$200.00	N/A

(Data available from 7/28/2016 forward)

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

Today's Range

Now: $102.05

$100.82

$103.21

50 Day Range

MA: $93.49

$81.77

$104.02

52 Week Range

Now: $102.05

$76.19

$123.74

Volume

392,266 shs

Average Volume

671,555 shs

Market Capitalization

$6.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Tandem Diabetes Care?

The following Wall Street research analysts have issued stock ratings on Tandem Diabetes Care in the last year: Barclays PLC, Craig Hallum, Guggenheim, Lake Street Capital, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, SVB Leerink LLC, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for TNDM.

What is the current price target for Tandem Diabetes Care?

9 Wall Street analysts have set twelve-month price targets for Tandem Diabetes Care in the last year. Their average twelve-month price target is $123.11, suggesting a possible upside of 20.6%. Lake Street Capital has the highest price target set, predicting TNDM will reach $150.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $90.00 for Tandem Diabetes Care in the next year.
View the latest price targets for TNDM.

What is the current consensus analyst rating for Tandem Diabetes Care?

Tandem Diabetes Care currently has 1 sell rating, 2 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TNDM will outperform the market and that investors should add to their positions of Tandem Diabetes Care.
View the latest ratings for TNDM.

What other companies compete with Tandem Diabetes Care?

Other companies that are similar to Tandem Diabetes Care include Teleflex, NovoCure, Insulet, Abiomed, Penumbra, Globus Medical, Hill-Rom, Integra LifeSciences, ShockWave Medical, Nevro, Inspire Medical Systems, Inari Medical, ICU Medical, AtriCure and Merit Medical Systems.

How do I contact Tandem Diabetes Care's investor relations team?

Tandem Diabetes Care's physical mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company's listed phone number is (858) 366-6900 and its investor relations email address is [email protected] The official website for Tandem Diabetes Care is www.tandemdiabetes.com.